Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Intravenous Antibiotics In Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates (≥ 35+0 weeks, 0-28 days old, ≥ 2 kg)~* Probable bacterial infection defined as clinical symptoms and/or maternal risk factors and elevated inflammatory markers for which empiric broad-spectrum antibiotic treatment was initiated and needs to be continued for \> 48 hours~* Clinically well~* Toleration of oral feeding without overt vomiting~* Signed informed consent~Exclusion Criteria:~* Proven bloodstream infection~* Absence of blood culture~* Severe localized infection (meningitis, osteomyelitis, necrotizing enterocolitis)~* Severe clinical sepsis (compromised circulation, need for mechanical ventilation)~* Continuous need for a central venous line~* Severe hyperbilirubinemia exceeding the exchange level~* Parents inability to administer medication~* Major congenital or syndromic anomalies

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Oral group (Type: ACTIVE_COMPARATOR): After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured.
- Intravenous group (Type: ACTIVE_COMPARATOR): Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).